Sagent Pharmaceuticals, Inc. (SGNT) Tops Q1 EPS by 16c

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q1 EPS of $0.16, $0.16 better than the analyst estimate of $0.00. Revenue for the quarter came in at $70.9 million versus the consensus estimate of $65.66 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.

You May Also Be Interested In

• Coherent posts a blowout Q4 and aggressive guidance, yet shares take a 5% haircut
• Bitgo Holdings, Inc. (BTGO) Reports Q2 Loss of $0.16
• EnerSys (ENS) Tops Q1 EPS by 84c; offers guidance